The U.S. Food and Drug Administration approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to improve blood sugar (glucose) control in adults with diabetes mellitus. Tresiba and Ryzodeg are long-acting insulins. Long-acting insulins play an essential role in the treatment of patients with type-1 diabetes and in patients with type-2 diabetes […]
The post Tresiba & Ryzodeg – long-acting insulins approved in US appeared first on Health Newstrack.
